The effect of varying analytical methods on estimates of anti-malarial clinical efficacy

Malaria Journal

Volumn 8, Issue 1, 2009, Pages

  Verret, Wendy J ^a   Dorsey, Grant ^b   Nosten, Francois ^c,d,e   Price, Ric N ^e,f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SHOKLO MALARIA RESEARCH UNIT   (Thailand)

^d MAHIDOL UNIVERSITY   (Thailand)

^e CHURCHILL HOSPITAL   (United Kingdom)

^f MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT;

AFRICA; ANALYTIC METHOD; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISEASE TRANSMISSION; FOLLOW UP; GENOTYPE; HUMAN; INTENTION TO TREAT; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALARIA; MODIFIED INTENTION TO TREAT; PER PROTOCOL; THAILAND; TREATMENT FAILURE; ANIMAL; CLINICAL TRIAL; DRUG COMBINATION; DRUG EFFECT; GENETICS; KAPLAN MEIER METHOD; MALARIA FALCIPARUM; METHODOLOGY; PARASITEMIA; PARASITOLOGY; PATIENT; PATIENT COMPLIANCE; PLASMODIUM FALCIPARUM; RISK; STATISTICAL ANALYSIS; STATISTICS; SURVIVAL;

AFRICA; ANIMALS; ANTIMALARIALS; CLINICAL TRIALS AS TOPIC; DATA INTERPRETATION, STATISTICAL; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; GENOTYPE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALARIA, FALCIPARUM; PARASITEMIA; PATIENT COMPLIANCE; PATIENT DROPOUTS; PLASMODIUM FALCIPARUM; RESEARCH DESIGN; RISK; SURVIVAL ANALYSIS; THAILAND; TREATMENT FAILURE;

EID: 65549137143     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-8-77     Document Type: Article

References (35)

1. The use of genotyping in antimalarial clinical trials: a systematic review of published studies from 1995-2005. WJ Collins B Greenhouse PJ Rosenthal G Dorsey, Malar J 2006 5 122 17169157 10.1186/1475-2875-5-122 (Pubitemid 46020967)
2. Guidelines for the treatment of malaria. WHO, Document No WHO/HTM/MAL/20061108
3. Methodological issues in the assessment of antimalarial drug treatment: analysis of 13 studies in eight African countries from 2001 to 2004. JP Guthmann L Pinoges F Checchi S Cousens S Balkan M van Herp D Legros P Olliaro, Antimicrob Agents Chemother 2006 50 3734 3739 16954313 10.1128/AAC.01618-05 (Pubitemid 44684888)
4. Revisiting the dsign of phase III clinical trials of antimalarial drugs for uncomplicated Plasmodium falciparum malaria. S Borrmann T Peto RW Snow W Gutteridge NJ White, PLoS Med 2008 5 e227 19018658 10.1371/journal.pmed.0050227
5. Different methodological approaches to the assessment of in vivo efficacy of three artemisinin-based combination antimalarial treatments for the treatment of uncomplicated falciparum malaria in African children. EA Ashley L Pinoges E Turyakira G Dorsey F Checchi H Bukirwa I van den Broek I Zongo PP Urruta M van Herp S Balkan WR Taylor P Olliaro JP Guthmann, Malar J 2008 7 154 18691429 10.1186/1475-2875-7-154
6. Methods and techniques for clinical trials on antimalarial drug efficacy: genotyping to identify parasite populations. Informal consultation organized by the Medicines for Malaria Venture and cosponsored by the World Health Organization Amsterdam, The Netherlands 2007
7. World Antimalarial Resistance Network I: clinical efficacy of antimalarial drugs. RN Price G Dorsey EA Ashley KI Barnes JK Baird U d'Alessandro PJ Guerin MK Laufer I Naidoo F Nosten P Olliaro CV Plowe P Ringwald CH Sibley K Stepniewska NJ White, Malar J 2007 6 119 17822532 10.1186/1475-2875-6-119 (Pubitemid 47561493)
8. Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria. WHO, Document No WHO/HTM/RBM2003.50
9. Effects of Plasmodium vivax malaria in pregnancy. F Nosten R McGready JA Simpson KL Thwai S Balkan T Cho L Hkirijaroen S Looareesuwan NJ White, Lancet 1999 354 546 549 10.1016/S0140-6736(98)09247-2 10470698 (Pubitemid 29381368)
10. The epidemiology of malaria in a Karen population on the western border of Thailand. C Luxemburger KL Thwai NJ White HK Webster DE Kyle L Maelankirri T Chongsuphajaisiddhi F Nosten, Trans R Soc Trop Med Hyg 1996 90 105 111 10.1016/S0035-9203(96)90102-9 8761562 (Pubitemid 26141072)
11. Application of genetic markers to the identification of recrudescent Plasmodium falciparum infections on the northwestern border of Thailand. A Brockman RE Paul TJ Anderson I Hackford L Phaiphun S Looareesuwan F Nosten KP Day, Am J Trop Med Hyg 1999 60 14 21 9988316 (Pubitemid 29065997)
12. Some considerations in the design and interpretation of antimalarial drug trials in uncomplicated falciparum malaria. K Stepniewska NJ White, Malar J 2006 5 127 17187673 10.1186/1475-2875-5-127 (Pubitemid 46127298)
13. Control to elimination: implications for malaria research. BM Greenwood, Trends Parasitol 2008 24 449 454 10.1016/j.pt.2008.07.002 18760671
14. Amodiaquine, sulfadoxine-pyrimethamine, and combination therapy for uncomplicated falciparum malaria: a randomized controlled trial from Burkina Faso. I Zongo G Dorsey N Rouamba C Dokomajilar M Lankoande JB Ouedraogo PJ Rosenthal, Am J Trop Med Hyg 2005 73 826 832 16282288 (Pubitemid 41688453)
15. Artemether-lumefantrine versus amodiaquine plus sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Burkina Faso: a randomised non-inferiority trial. I Zongo G Dorsey N Rouamba H Tinto C Dokomajilar RT Guiguemde PJ Rosenthal JB Ouedraogo, Lancet 2007 369 491 498 10.1016/S0140-6736(07)60236-0 17292769 (Pubitemid 46223467)
16. Artemisinin versus nonartemisinin combination therapy for uncomplicated malaria: randomized clinical trials from four sites in Uganda. A Yeka K Banek N Bakyaita SG Staedke MR Kamya A Talisuna F Kironde SL Nsobya A Kilian M Slater A Reingold PJ Rosenthal F Wabwire-Mangen G Dorsey, PLoS Medicine 2005 2 e190 16033307 10.1371/journal.pmed.0020190 (Pubitemid 46179276)
17. Combination treatments for uncomplicated falciparum malaria in Kampala, Uganda: randomised clinical trial. SG Staedke A Mpimbaza MR Kamya BK Nzarubara G Dorsey PJ Rosenthal, Lancet 2004 364 1950 1957 10.1016/S0140-6736(04)17478-3 15567011 (Pubitemid 39574598)
18. Combination therapy for uncomplicated falciparum malaria in Ugandan children: a randomized trial. G Dorsey S Staedke TD Clark D Njama-Meya B Nzarubara C Maiteki-Sebuguzi C Dokomajilar MR Kamya PJ Rosenthal, JAMA 2007 297 2210 2219 10.1001/jama.297.20.2210 17519410
19. Sulfadoxine-pyrimethamine plus chloroquine or amodiaquine for uncomplicated falciparum malaria: a randomized, multisite trial to guide national policy in Uganda. N Bakyaita G Dorsey A Yeka K Banek SG Staedke MR Kamya A Talisuna F Kironde S Nsobya A Kilian A Reingold PJ Rosenthal F Wabwire-Mangen, Am J Trop Med Hyg 2005 72 573 580 15891132 (Pubitemid 41278826)
20. Artemisinin combination therapies for treatment of uncomplicated malaria in Uganda. H Bukirwa A Yeka MR Kamya A Talisuna K Banek N Bakyaita JB Rwakimari PJ Rosenthal F Wabwire-Mangen G Dorsey SG Staedke, PLoS Clin Trials 2006 1 e7 16871329 10.1371/journal.pctr.0010007
21. Randomized comparison of amodiaquine plus sulfadoxine-pyrimethamine, artemether-lumefantrine, and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Burkina Faso. I Zongo G Dorsey N Rouamba C Dokomajilar Y Sere PJ Rosenthal JB Ouedraogo, Clin Infect Dis 2007 45 1453 1461 10.1086/522985 17990228
22. Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment of malaria: a randomized trial. MR Kamya A Yeka H Bukirwa M Lugemwa JB Rwakimari SG Staedke AO Talisuna B Greenhouse F Nosten PJ Rosenthal F Wabwire-Mangen G Dorsey, PLoS Clin Trials 2007 2 e20 17525792 10.1371/journal.pctr.0020020 (Pubitemid 46860146)
23. Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treating uncomplicated malaria: a randomized trial to guide policy in Uganda. A Yeka G Dorsey MR Kamya A Talisuna M Lugemwa JB Rwakimari SG Staedke PJ Rosenthal F Wabwire-Mangen H Bukirwa, PLoS ONE 2008 3 e2390 18545692 10.1371/journal. pone.0002390
24. No evidence of cardiotoxicity during antimalarial treatment with artemether-lumefantrine. M van Vugt F Ezzet F Nosten I Gathmann P Wilairatana S Looareesuwan NJ White, Am J Trop Med Hyg 1999 61 964 967 10674679 (Pubitemid 30084122)
25. Treatment of uncomplicated multidrug-resistant falciparum malaria with artesunate-atovaquone-proguanil. M van Vugt E Leonardi L Phaipun T Slight KL Thway R McGready A Brockman L Villegas S Looareesuwan NJ White F Nosten, Clin Infect Dis 2002 35 1498 1504 10.1086/344901 12471569 (Pubitemid 36020693)
26. Molecular and pharmacological determinants of the therapeutic response to artemether-lumefantrine in multidrug-resistant Plasmodium falciparum malaria. RN Price AC Uhlemann M van Vugt A Brockman R Hutagalung S Nair D Nash P Singhasivanon TJ Anderson S Krishna NJ White F Nosten, Clin Infect Dis 2006 42 1570 1577 10.1086/503423 16652314 (Pubitemid 43752645)
27. Artemether-lumefantrine for the treatment of multidrug-resistant falciparum malaria. M van Vugt S Looareesuwan P Wilairatana R McGready L Villegas I Gathmann R Mull A Brockman NJ White F Nosten, Trans R Soc Trop Med Hyg 2000 94 545 548 10.1016/S0035-9203(00)90082-8 11132386
28. The in vivo efficacy and in vitro sensitivity of artesunate and mefloquine during 12 years of continuous deployment on the Thai-Myanmar border. VI Carrara M Barends EA Ashley RN Price A Brockman TJ Anderson K Stepniewska R McGready L Phaiphun S Proux P Preechapkornkul J Zwang M Imwong S Pukritayakamee S Singhasivanon NJ White F Nosten, PLoS ONE 2009 19234601
29. Artesunate/mefloquine treatment of multi-drug resistant falciparum malaria. RN Price F Nosten C Luxemburger M van Vugt L Phaipun T Chongsuphajaisiddhi NJ White, Trans R Soc Trop Med Hyg 1997 91 574 577 10.1016/S0035-9203(97)90032-8 9463672 (Pubitemid 27478651)
30. Randomized, controlled dose-optimization studies of dihydroartemisinin- piperaquine for the treatment of uncomplicated multidrug-resistant falciparum malaria in Thailand. EA Ashley S Krudsood L Phaiphun S Srivilairit R McGready W Leowattana R Hutagalung P Wilairatana A Brockman S Looareesuwan F Nosten NJ White, J Infect Dis 2004 190 1773 1782 10.1086/425015 15499533 (Pubitemid 39487822)
31. Randomized comparison of artemether-benflumetol and artesunate-mefloquine in treatment of multidrug-resistant falciparum malaria. M van Vugt A Brockman B Gemperli C Luxemburger I Gathmann C Royce T Slight S Looareesuwan NJ White F Nosten, Antimicrob Agents Chemother 1998 42 135 139 9449273 (Pubitemid 28053339)
32. An open label randomized comparison of mefloquine-artesunate as separate tablets vs. a new co-formulated combination for the treatment of uncomplicated multidrug-resistant falciparum malaria in Thailand. EA Ashley KM Lwin R McGready WH Simon L Phaiphun S Proux N Wangseang W Taylor K Stepniewska W Nawamaneerat KL Thwai M Barends W Leowattana P Olliaro P Singhasivanon NJ White F Nosten, Trop Med Int Health 2006 11 1653 1660 10.1111/j.1365-3156.2006.01724.x 17054744 (Pubitemid 44624367)
33. Artesunate versus artemether in combination with mefloquine for the treatment of multidrug-resistant falciparum malaria. RN Price F Nosten C Luxemburger A Kham A Brockman T Chongsuphajaisiddhi NJ White, Trans R Soc Trop Med Hyg 1995 89 523 527 10.1016/0035-9203(95)90094-2 8560531
34. Treatment of multidrug-resistant Plasmodium falciparum malaria with 3-day artesunate-mefloquine combination. F Nosten C Luxemburger FO ter Kuile C Woodrow JP Eh T Chongsuphajaisiddhi NJ White, J Infect Dis 1994 170 971 977 7930743 (Pubitemid 24296580)
35. Oral artesunate in the treatment of uncomplicated hyperparasitemic falciparum malaria. C Luxemburger F Nosten SD Raimond T Chongsuphajaisiddhi NJ White, Am J Trop Med Hyg 1995 53 522 525 7485711